Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Maximizing quality in clinical trials is emphasized at community workshop

A community workshop sponsored by SNM's Clinical Trials Network (CTN) officially kicked off on Feb. 1, in Albuquerque, N.M., and presented participants with a series of educational sessions on the use of molecular imaging in clinical trials for investigational therapeutic drugs.

3 Feb 2010

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Dayton Physicians LLC, one of Ohio’s leading multi-specialty cancer treatment centers, has selected IntrinsiQ’s IntelliDose® clinical software to manage complex chemotherapy treatment, safely and efficiently.

3 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

FDA approved 53 new oncology and hematology drugs between 2005 and 2007

Over a two and half year period, beginning in 2005 when the U.S. Food and Drug Administration's oncology drug product's office began reviewing marketing applications, a total of 60 new oncology and hematology drugs were reviewed, of which 53 were approved, according to a new article published online January 29 in the Journal of the National Cancer Institute.

30 Jan 2010

IDEXX Laboratories reports revenues for fourth-quarter of 2009

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2009 increased 11% to $270.3 million, from $243.3 million for the fourth quarter of 2008.

29 Jan 2010

ASH offers hematologists a new resource for earning CME credits

The American Society of Hematology (ASH) now offers physicians who diagnose and treat blood disorders a new resource for earning continuing medical education (CME) credits while staying abreast of the latest clinical strategies in the rapidly changing field of hematology.

29 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

Adipose tissue, a promising new source of HSPCs

Bone marrow is a leading source of adult stem cells, which are increasingly used for research and therapeutic interventions, but extracting the cells is an arduous and often painful process. Now, researchers have found evidence that fat tissue, known as adipose tissue, may be a promising new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells (HSPCs), according to astudy prepublished online in Blood, the official journal of the American Society of Hematology.

28 Jan 2010

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.

24 Jan 2010

Ipsen and Inspiration Biopharmaceuticals form strategic partnership

Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals ("Inspiration") to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio.

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Ipsen and Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that they have entered into a partnership to create a world leading hemophilia franchise. The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

21 Jan 2010

Gene study could result in personalized therapies for patients with deadly brain cancer

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process.

20 Jan 2010

Gene variant predisposes humans to develop acute myeloid leukemia, says study

A large international research group led by Dr. Tarik M-r-y, a researcher at the Institut de recherches cliniques de Montr-al (IRCM), has discovered that a variant of the gene "Growth Factor Independence 1" (GFI1) predisposes humans to develop acute myeloid leukemia (AML), a certain subtype of blood cancer.

20 Jan 2010

Researchers propose a new model for breast cell differentiation

A study by researchers at Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and Tufts Medical Center improves our current understanding of the origins of breast cancer. The

19 Jan 2010

New report providing insight for companies developing therapies to treat hematologic malignancies published

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.

18 Jan 2010

New neuroprotective drug trial for people with traumatic brain injuries

A clinical trial of a new neuroprotective drug for people with traumatic brain injuries will be offered to patients seen in UC Davis Medical Center's level-1 trauma center, through an $8 million grant funded by the Congressionally Directed Medical Research Program of the U.S. Department of Defense.

18 Jan 2010

Treatment for metastatic tumor based on its unique protein makeup

Imagine if treatments for disease could be based not on a patient's diagnosis but instead on the characteristics of their tissue. By identifying and decoding the cryptic messages hidden deep inside the human proteome, scientists and physicians who study personalized medicine are seeking more effective treatments and disease management for patients.

18 Jan 2010

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.

13 Jan 2010